Literature DB >> 34165350

AmotL2, IQGAP1, and FKBP51 Scaffold Proteins in Glioblastoma Stem Cell Niches.

Deborah Rotoli1,2,3, Lucio Díaz-Flores4, Ricardo Gutiérrez4, Manuel Morales5, Julio Ávila1,2, Pablo Martín-Vasallo1,2.   

Abstract

Glioma stem cells (GSCs) live in a continuous process of stemness reprogramming to achieve specific cell commitment within the so-called GSC niches, specifically located in periarteriolar regions. In this review, we analyze the expression levels, cellular and subcellular location, and role of three scaffold proteins (IQGAP1, FKBP51, and AmotL2) in GSC niches. Scaffold proteins contribute to cell differentiation, migration, and angiogenesis in glioblastoma. It could be of diagnostic interest for establishing stages, for therapeutic targets, and for improving glioblastoma prognosis, which is still at the experimental level.

Entities:  

Keywords:  AmotL2; IQGAP1; and FKBP51; angiogenesis; glioblastoma stem cells; scaffold proteins; stem cell niche; stemness; tumor heterogeneity; tumor immune infiltrate; tumor microenvironment

Mesh：

Substances：

Year:  2021        PMID： 34165350      PMCID： PMC8721575          DOI： 10.1369/00221554211025480

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN： 0022-1554            Impact factor:   2.479


  67 in total

1.  Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: its overexpression in carcinomas and association with invasion fronts.

Authors:  Kazuki Nabeshima; Yoshiya Shimao; Teruhiko Inoue; Masashi Koono
Journal:  Cancer Lett       Date:  2002-02-08       Impact factor: 8.679

2.  S100P is a novel interaction partner and regulator of IQGAP1.

Authors:  Annika Heil; Ali Reza Nazmi; Max Koltzscher; Michaela Poeter; Judith Austermann; Nicole Assard; Jacques Baudier; Kozo Kaibuchi; Volker Gerke
Journal:  J Biol Chem       Date:  2010-12-22       Impact factor: 5.157

3.  IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients.

Authors:  Kerrie L McDonald; Maree G O'Sullivan; Jonathon F Parkinson; Janet M Shaw; Cathy A Payne; Janice M Brewer; Lawrence Young; Dianne J Reader; Helen T Wheeler; Raymond J Cook; Michael T Biggs; Nicholas S Little; Charlie Teo; Glenn Stone; Bruce G Robinson
Journal:  J Neuropathol Exp Neurol       Date:  2007-05       Impact factor: 3.685

Review 4.  IQGAP1 regulation and roles in cancer.

Authors:  Michael Johnson; Manisha Sharma; Beric R Henderson
Journal:  Cell Signal       Date:  2009-03-06       Impact factor: 4.315

5.  Dynamic mitochondrial-nuclear redistribution of the immunophilin FKBP51 is regulated by the PKA signaling pathway to control gene expression during adipocyte differentiation.

Authors:  Judith Toneatto; Sergio Guber; Nancy L Charó; Sebastián Susperreguy; Jessica Schwartz; Mario D Galigniana; Graciela Piwien-Pilipuk
Journal:  J Cell Sci       Date:  2013-10-07       Impact factor: 5.285

Review 6.  IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis.

Authors:  Colin D White; Matthew D Brown; David B Sacks
Journal:  FEBS Lett       Date:  2009-05-09       Impact factor: 4.124

7.  Angiomotin regulates endothelial cell migration during embryonic angiogenesis.

Authors:  Karin Aase; Mira Ernkvist; Lwaki Ebarasi; Lars Jakobsson; Arindam Majumdar; Chunling Yi; Olivier Birot; Yue Ming; Anders Kvanta; Dan Edholm; Pontus Aspenström; Joseph Kissil; Lena Claesson-Welsh; Akihiko Shimono; Lars Holmgren
Journal:  Genes Dev       Date:  2007-08-15       Impact factor: 11.361

8.  FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.

Authors:  Li Ni; Chun-Song Yang; Daniel Gioeli; Henry Frierson; David O Toft; Bryce M Paschal
Journal:  Mol Cell Biol       Date:  2010-01-04       Impact factor: 4.272

9.  Expression and localization of the immunophilin FKBP51 in colorectal carcinomas and primary metastases, and alterations following oxaliplatin-based chemotherapy.

Authors:  Deborah Rotoli; Manuel Morales; María Del Carmen Maeso; María Del Pino García; Araceli Morales; Julio Ávila; Pablo Martín-Vasallo
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

10.  A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.

Authors:  Paolo D'Arrigo; Michele Russo; Anna Rea; Martina Tufano; Elia Guadagno; Maria Laura Del Basso De Caro; Roberto Pacelli; Felix Hausch; Stefania Staibano; Gennaro Ilardi; Silvia Parisi; Maria Fiammetta Romano; Simona Romano
Journal:  Oncotarget       Date:  2017-07-17
View more
  4 in total

Review 1.  Cell Biology Meets Cell Metabolism: Energy Production Is Similar in Stem Cells and in Cancer Stem Cells in Brain and Bone Marrow.

Authors:  Cornelis J F van Noorden; Barbara Breznik; Metka Novak; Amber J van Dijck; Saloua Tanan; Miloš Vittori; Urban Bogataj; Noëlle Bakker; Joseph D Khoury; Remco J Molenaar; Vashendriya V V Hira
Journal:  J Histochem Cytochem       Date:  2021-10-29       Impact factor: 2.479

2.  FKBP51, AmotL2 and IQGAP1 Involvement in Cilastatin Prevention of Cisplatin-Induced Tubular Nephrotoxicity in Rats.

Authors:  Rebeca González-Fernández; María Ángeles González-Nicolás; Manuel Morales; Julio Ávila; Alberto Lázaro; Pablo Martín-Vasallo
Journal:  Cells       Date:  2022-05-09       Impact factor: 7.666

3.  FKBP51 promotes invasion and migration by increasing the autophagic degradation of TIMP3 in clear cell renal cell carcinoma.

Authors:  Shengying Qin; Muyun Wei; Shaowei Mao; Di Zhang; Luan Chen; Jie Tan; Yunpeng Chu; Sijia Huang; Wenqi Zhou; Hengwei Qin; Qinghua Xia; Yueran Zhao; Rongxiu Li
Journal:  Cell Death Dis       Date:  2021-10-01       Impact factor: 8.469

4.  CDC42-IQGAP Interactions Scrutinized: New Insights into the Binding Properties of the GAP-Related Domain.

Authors:  Niloufar Mosaddeghzadeh; Silke Pudewell; Farhad Bazgir; Neda S Kazemein Jasemi; Oliver H F Krumbach; Lothar Gremer; Dieter Willbold; Radovan Dvorsky; Mohammad R Ahmadian
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.